NCT04292223

Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 29 (actual)
• Sponsor: ACADIA Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 40 Years
• Healthy volunteers: Not accepted

Summary

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

Detailed description

This study will be conducted as a 16-week, multi-center, single-arm, open-label study. Pimavanserin will be administered at a dose of 34 mg to approximately 50 subjects with PDP

Conditions

• Parkinson Disease Psychosis

Interventions

Type	Name	Description
DRUG	Pimavanserin	Pimavanserin 34 mg (provided as 1×34 mg capsule), administered orally, once daily for 16 weeks

Timeline

• Start date: 2020-02-10
• Primary completion: 2022-04-26
• Completion: 2022-04-26
• First posted: 2020-03-03
• Last updated: 2025-01-14
• Results posted: 2025-01-14

Locations

18 sites across 1 country: United States

Regulatory

• FDA-regulated drug study